Skip to main content
Clinical Trials/NCT05119556
NCT05119556
Active, Not Recruiting
N/A

Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease (Tele-COPD)

University of Alabama at Birmingham20 sites in 1 country301 target enrollmentJune 28, 2022

Overview

Phase
N/A
Intervention
Standard of Care
Conditions
Chronic Obstructive Pulmonary Disease
Sponsor
University of Alabama at Birmingham
Enrollment
301
Locations
20
Primary Endpoint
All-cause hospitalization within 30 days post discharge for an index admission for COPD exacerbation
Status
Active, Not Recruiting
Last Updated
19 days ago

Overview

Brief Summary

The purpose of this study is to compare the efficacy and safety of a real time video telehealth pulmonary rehabilitation intervention with standard of care in patients hospitalized for an exacerbation of chronic obstructive pulmonary disease (COPD) to determine the impact on hospital readmissions and respiratory morbidity, and to investigate the cost-effectiveness of the intervention.

Detailed Description

This is a 52 week, prospective, randomized controlled, phase 3, multi-center clinical trial (n=768 at 14 clinical sites) comparing the efficacy and safety of a real time video telehealth pulmonary rehabilitation intervention with standard of care in patients hospitalized for COPD exacerbation to determine the impact on hospital readmissions and respiratory morbidity, and to investigate the cost-effectiveness of the intervention. All patients with a clinical diagnosis of COPD who are hospitalized for an acute exacerbation of COPD at each clinical site will be considered for inclusion. Interested participants will be seen at 8 (-3 to +4) days after discharge from the hospital. At this visit, participants will be randomized 1:1, in varying blocks, stratified by site, to video telehealth PR plus standard of care versus standard of care alone. The telehealth intervention will involve 3 exercise sessions a week for 12 weeks. Exercise sessions will be provided in real-time via live two-way videoconferencing using a HIPAA-compliant app on an encrypted smart phone or similar device. Each session will be standardized to include cardiovascular (aerobic) training, strength (resistance) training, breathing exercises, and education that includes smoking cessation counselling where applicable, inhaler use techniques, diet, and nutrition. Participants in both the intervention and control arms will receive standard of care per local guidance. During the period of active intervention, participants in both arms will be contacted monthly to ascertain any exacerbations. Questionnaires and assessments of function will be administered at the baseline 8 day visit and at completion of the intervention at 13 weeks. Subsequently, participants in both arms will be called 3-monthly to ascertain healthcare utilization, and questionnaires and assessments of function will be repeated at the end of the follow-up period at 52 weeks.

Registry
clinicaltrials.gov
Start Date
June 28, 2022
End Date
February 27, 2028
Last Updated
19 days ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Surya P Bhatt

Professor of Medicine

University of Alabama at Birmingham

Eligibility Criteria

Inclusion Criteria

  • Age 40 or greater
  • Clinical diagnosis of COPD
  • Hospitalized for acute exacerbation of COPD.
  • Be willing to adhere to trial and follow-up procedures and give informed consent

Exclusion Criteria

  • Secondary diagnosis of congestive heart failure that is severe as documented by active symptoms, New York Heart Association (NYHA) functional classification IV or left ventricular ejection fraction \<25% on echocardiography
  • Other respiratory conditions that could confound the diagnosis such as asthma, pulmonary fibrosis, bronchiectasis, and lung cancer. Participants with pneumonic exacerbations of COPD will be included.
  • Primary diagnosis of COVID pneumonia. Individuals with incidentally detected COVID or persistently positive for COVID but deemed to be convalescent will not be excluded.
  • Active cancers on chemotherapy or radiation therapy
  • Immunosuppressed states predisposing to frequent hospitalizations including uncontrolled HIV/AIDS
  • Active or recent (within 1 month) myocardial infarction
  • Angina not well-controlled by medication
  • Unstable cardiac arrhythmias, atrial or ventricular
  • Supplemental oxygen requirement greater than 5 liters per minute at either rest or with exertion
  • Significant cognitive dysfunction, including dementia, that in opinion of investigator would impair ability to safely or effectively engage in study protocol

Arms & Interventions

Standard of Care

Participants will receive standard of care for COPD management per local guidance. In addition, they will receive 4-weekly phone calls for 13 weeks post discharge to inquire about health status and exacerbations.

Video Telehealth Pulmonary Rehabilitation

In addition to standard of care, participants will be asked to participate in rehabilitation sessions administered at home via live videoconferencing for approximately 60 minutes a session, three times a week. A total of 36 sessions will be planned to be completed by week 13 post-discharge. Exacerbations and health status will be ascertained every 4-weeks for 13 weeks.

Intervention: Video Telehealth Pulmonary Rehabilitation

Outcomes

Primary Outcomes

All-cause hospitalization within 30 days post discharge for an index admission for COPD exacerbation

Time Frame: 30 days

Hospitalizations will be ascertained via weekly phone calls. Hospitalization for any reason will be considered a primary event when it occurs within the first 30 days after index hospitalization.

Change in six-minute walk distance

Time Frame: 13 weeks

The six-minute walk test is an assessment of functional capacity, and is the distance walked in 6 minutes. The minimum clinically important difference (MCID) for COPD is 26 m.

Change in St. George's Respiratory Questionnaire

Time Frame: 13 weeks

The St. George's Respiratory Questionnaire (SGRQ) is a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. It consists of 40 questions, and scores range from 0 to 100, with higher scores indicating worse quality of life. The minimum clinically important difference (MCID) is 4 units.

Cost Savings

Time Frame: 30 days

Cost saving will be estimated by comparing costs of the intervention and savings resulting from readmission reduction within 30 days.

Change in the University of California, San Diego Shortness of Breath Questionnaire

Time Frame: 13 weeks

The University of California, San Diego Shortness of Breath Questionnaire (SOBQ) is a 24-question, self-administered questionnaire which rates dyspnea associated with activities of daily living. Scores range from 0 to 120, with higher scores indicating greater dyspnea. The minimum clinically important difference (MCID) is 5.

Cost per Quality Adjusted Life Year Gained

Time Frame: 52 weeks

Cost-effectiveness will be calculated by comparing Telehealth PR with Standard of Care using incremental cost-effectiveness ratios.

Secondary Outcomes

  • 90-days all cause readmission rate(13 weeks)
  • The adverse events (AEs) and serious adverse events (SAEs)(13 weeks)
  • Change in COPD Assessment Test score(13 weeks)
  • Change in 30-second Sit-to-Stand Test(13 weeks)
  • Change in Pittsburgh Sleep Quality Index(13 weeks)
  • Change in the Clinical visit-PROactive Physical Activity Score(13 weeks)
  • Change in Pulmonary Rehabilitation Adapted Index of Self-Efficacy(13 weeks)
  • Change in Hospital Anxiety and Depression Scale(13 weeks)
  • Change in The modified Medical Research Council score(13 weeks)

Study Sites (20)

Loading locations...

Similar Trials